This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
30 Jan 2011

GSK, Actelion Put Failed Sleep Drug to Rest

GlaxoSmithKline and Actelion announced they are discontinuing development of their late-stage insomnia drug almorexant due to tolerance concerns.

GlaxoSmithKline and Actelion issued a statement on January 28 saying that they have discontinued the development of the insomnia drug almorexant, a dual orexin receptor antagonist, over concerns about patients' tolerance of the drug.
 

Related News